Cargando…

Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery

One of the major reasons why central nervous system (CNS)-drug development has been challenging in the past, is the barriers that prevent substances entering from the blood circulation into the brain. These barriers include the blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), blood-cereb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huttunen, Kristiina M., Terasaki, Tetsuya, Urtti, Arto, Montaser, Ahmed B., Uchida, Yasuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Expert Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246989/ https://www.ncbi.nlm.nih.gov/pubmed/35257288 http://dx.doi.org/10.1007/s11095-022-03193-2

Ejemplares similares

L-Type amino acid transporter 1 as a target for drug delivery
por: Puris, Elena, et al.
Publicado: (2020)

Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for l-Type Amino Acid Transporter 1-Utilizing Prodrugs
por: Huttunen, Johanna, et al.
Publicado: (2023)

Astrocyte-Targeted Transporter-Utilizing Derivatives of Ferulic Acid Can Have Multifunctional Effects Ameliorating Inflammation and Oxidative Stress in the Brain
por: Montaser, Ahmed, et al.
Publicado: (2019)

Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?
por: Puris, Elena, et al.
Publicado: (2022)

L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels
por: Montaser, Ahmed, et al.
Publicado: (2020)

Metformin – a Future Therapy for Neurodegenerative Diseases: Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla
por: Markowicz-Piasecka, Magdalena, et al.
Publicado: (2017)

Precision medicine: from pharmacogenomics to pharmacoproteomics
por: Chambliss, Allison B., et al.
Publicado: (2016)

Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival
por: Tampio, Janne, et al.
Publicado: (2020)

On The Rate and Extent of Drug Delivery to the Brain
por: Hammarlund-Udenaes, Margareta, et al.
Publicado: (2007)

Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis
por: Markowicz-Piasecka, Magdalena, et al.
Publicado: (2020)

Pharmacoproteomic characterisation of human colon and rectal cancer
por: Frejno, Martin, et al.
Publicado: (2017)

Aminopeptidase B can bioconvert L-type amino acid transporter 1 (LAT1)-utilizing amide prodrugs in the brain
por: Hugele, Agathe, et al.
Publicado: (2022)

Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands
por: Huttunen, Johanna, et al.
Publicado: (2021)

L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production
por: Tampio, Janne, et al.
Publicado: (2022)

Barriers to Non-Viral Vector-Mediated Gene Delivery in the Nervous System
por: Pérez-Martínez, Francisco C., et al.
Publicado: (2011)

An Atlas of the Quantitative Protein Expression of Anti-Epileptic-Drug Transporters, Metabolizing Enzymes and Tight Junctions at the Blood–Brain Barrier in Epileptic Patients
por: Sato, Risa, et al.
Publicado: (2021)

Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes
por: Calamia, Valentina, et al.
Publicado: (2010)

A pharmacoproteomic study confirms the synergistic effect of chondroitin sulfate and glucosamine
por: Calamia, Valentina, et al.
Publicado: (2014)

A pharmacoproteomic landscape of organotypic intervention responses in Gram-negative sepsis
por: Mohanty, Tirthankar, et al.
Publicado: (2023)

Proteomics-Based Transporter Identification by the PICK Method: Involvement of TM7SF3 and LHFPL6 in Proton-Coupled Organic Cation Antiport at the Blood–Brain Barrier
por: Kurosawa, Toshiki, et al.
Publicado: (2022)

Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs)
por: Huttunen, Johanna, et al.
Publicado: (2022)

Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations
por: Nandal, Savita, et al.
Publicado: (2017)

Genetic variation, brain, and intelligence differences
por: Deary, Ian J., et al.
Publicado: (2021)

Attenuation of prostaglandin E(2 )elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole
por: Akanuma, Shin-ichi, et al.
Publicado: (2011)

In Vivo Methods to Study Uptake of Nanoparticles into the Brain
por: van Rooy, Inge, et al.
Publicado: (2010)

Connectome imaging for mapping human brain pathways
por: Shi, Y, et al.
Publicado: (2017)

Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport
por: Sadiq, Muhammad Waqas, et al.
Publicado: (2015)

Discovery of the Consistently Well-Performed Analysis Chain for SWATH-MS Based Pharmacoproteomic Quantification
por: Fu, Jianbo, et al.
Publicado: (2018)

Brain age and other bodily ‘ages’: implications for neuropsychiatry
por: Cole, James H., et al.
Publicado: (2018)

Caring for traumatic brain injury in children can be a challenge!
por: Chen, Chun-Yu, et al.
Publicado: (2011)

Amino acid PET and MR perfusion imaging in brain tumours
por: Filss, Christian P., et al.
Publicado: (2017)

Modeling Alzheimer’s disease with iPSC-derived brain cells
por: Penney, Jay, et al.
Publicado: (2019)

Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer
por: Kwon, Inchan, et al.
Publicado: (2007)

A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood–brain barrier in ddY, FVB, and C57BL/6J mice
por: Uchida, Yasuo, et al.
Publicado: (2013)

Toward a conceptual framework for early brain and behavior development in autism
por: Piven, J, et al.
Publicado: (2017)

Maternal brain reactive antibodies profile in autism spectrum disorder: an update
por: Bagnall-Moreau, Ciara, et al.
Publicado: (2023)

Remembering through the genome: the role of chromatin states in brain functions and diseases
por: Arzate-Mejia, Rodrigo G., et al.
Publicado: (2023)

Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT
por: Pitkonen, Miia, et al.
Publicado: (2012)

Risk-benefit decision making in traumatic brain injury: Ratios, realities, results
por: Chan, Chee M, et al.
Publicado: (2012)

From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
por: Rogers, G B, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sgei3hdncrcq92farb9tt2cqp3